AI is Comprehensively Reshaping the Industry Value Chain
1. The AI-Driven "Super Cycle" for New Drugs is Approaching
The application of AI in target discovery, molecular generation, and clinical trial design is transitioning from experimentation to scale, exemplified by collaborations such as the NVIDIA/Lilly AI drug discovery alliance and the commercialization of Google DeepMind's AlphaFold 3. The market anticipates that the first new drugs fully designed and optimized by AI will enter critical clinical stages within the next 2-3 years.
2. AI Optimizes Clinical Operations and Supply Chains
Leading companies like Pfizer and Novartis leverage AI to predict clinical trial enrollment rates and optimize research site selection, significantly shortening R&D cycles. The application of AI models in forecasting active pharmaceutical ingredient (API) demand and managing cold chain logistics has greatly enhanced supply chain resilience and efficiency.
Recommended Posts
-
27-29th.April.2027 Booth No.L21 -
22-24th.April.2025
-
The EU's Key Medicines Act has entered the implementation phase, requiring the establishment of minimum inventories for key medicines and an increase in the local production ratio of active pharmaceutical ingredients (APIs). The United States continues to support domestic biomanufacturing through tools such as the Defense Production Act.
